3. Activity Goals

4. Incidence of Basal Cell Carcinoma (BCC)

5. Standard Therapies: Non-Melanoma Skin Cancer (NMSC)

6. Risk Factors

7. Risk Factors (cont)

8. Prognosis

9. Demographics

10. Mohs Micrographic Surgery (MMS)a

11. The MMS Procedure Description and Illustration

12. Therapies for BCC

13. Combined Topical Field Therapies

14. Photodynamic Therapy (PDT) Procedure

15. Topical d - ALA

16. Role of PDT in Management of Basal Cell Nevus Syndrome (BCNS)

17. BCNS Clinical Criteria

18. Investigator-Initiated, Randomized, Double-Blinded Trial for 18 months

19. 2 vs 29 New BCCs Per Year

20. Mechanism of Aberrant Hedgehog Signaling

21. Aberrant Hedgehog Signaling

22. Response in Patient With Metastatic Disease

23. Phase 1 Study of GDC-0449

24. ERIVANCE Phase 2 for BCC

25. Mechanisms of Acquired Resistance

26. Decrease in Tumor Size by IRF in the Metastatic Cohort

27. Comparison of Hedgehog Inhibitors

28. IPI-926 Phase 1 Study

29. Best Curative Therapy

30. MMS: Disadvantages

31. Combination Therapies

32. Radiotherapy

33. Challenges With Anti-SMO

34. Conclusions